The decline follows the company's refusal to halt all shipments of its Elevidys gene therapy, despite reports linking three ...

Shares in Europe and Asia are mostly higher after U.S. stocks claimed their third straight winning week. U.S. futures ...

An unusual public feud between the Food and Drug Administration and a maker of gene therapies for rare diseases could test ...

Sarepta stock (SRPT) declined 5% in premarket trade, after falling 36% on Friday, when it disclosed a patient death due to liver failure.